Exbio — Research products — Antibodies — CD and related antigens — Anti-Hu CD19 Biotin

Anti-Hu CD19 Biotin

Anti-Hu CD19 Biotin
Regulatory status
RUO
Antigen
CD19
Clone
LT19
Format
Biotin
Reactivity
Human
Application
IP, FC (QC tested)
Variant
0.1 mg
1B-305-C100
Out of stock
180.00 USD
0.025 mg
1B-305-C025
Out of stock
90.00 USD
Variant
0.1 mg
11-261-C100
In stock
180.00 USD
0.1 mg
11-261-C100
In stock
90.00 USD
Contact distributor
Product details
Images
References
Isotype
Mouse IgG1
Specificity
The antibody LT19 reacts with an extracellular epitope of CD19 (B4), a 95 kDa type I transmembrane glycoprotein (immunoglobulin superfamily) expressed on B lymphocytes and follicular dendritic cells; it is lost on plasma cells.
Workshop
HLDA X
Application
IP, FC (QC tested)
Application details
Flow cytometry: Recommended dilution: 3-5 μg/ml.
Reactivity
Human
Immunogen
Daudi human Burkitt lymphoma cell line
Other names
B4, Leu-12, CVID3
Concentration
1 mg/ml
Preparation
The purified antibody is conjugated with biotin-LC-NHS under optimum conditions. The reagent is free of unconjugated biotin.
Formulation
Phosphate buffered saline (PBS) solution with 15 mM sodium azide
Storage and handling
Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.
Exbio licence note
The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.
1B-305 FC
Flow cytometry analysis (surface staining) of human peripheral blood cells with anti-human CD19 (LT19) biotin.

General references:

Shi X, Xie C, Chang S, Zhou XJ, Tedder T, Mohan C: CD19 hyperexpression augments Sle1-induced humoral autoimmunity but not clinical nephritis. Arthritis Rheum. 2007 Sep;56(9):3057-69.
PubMed
van Zelm MC, Reisli I, van der Burg M, Castaño D, van Noesel CJ, van Tol MJ, Woellner C, Grimbacher B, Patiño PJ, van Dongen JJ, Franco JL: An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med. 2006 May 4;354(18):1901-12.
PubMed
Inabe K, Kurosaki T: Tyrosine phosphorylation of B-cell adaptor for phosphoinositide 3-kinase is required for Akt activation in response to CD19 engagement. Blood. 2002 Jan 15;99(2):584-9.
PubMed
Fujimoto M, Poe JC, Jansen PJ, Sato S, Tedder TF: CD19 amplifies B lymphocyte signal transduction by regulating Src-family protein tyrosine kinase activation. J Immunol. 1999 Jun 15;162(12):7088-94.
PubMed

Product specific references:

Lin CW, Liu TY, Chen SU, Wang KT, Medeiros LJ, Hsu SM: CD94 1A transcripts characterize lymphoblastic lymphoma/leukemia of immature natural killer cell origin with distinct clinical features. Blood. 2005 Nov 15;106(10):3567-74. Epub 2005 Jul 26.
PubMed
Stehlíková O, Chovancová J, Tichý B, Krejčí M, Brychtová Y, Panovská A, Francová Skuhrová H, Burčková K, Borský M, Loja T, Mayer J, Pospíšilová S, Doubek M: Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice. Int J Lab Hematol. 2013 Sep 13. doi: 10.1111/ijlh.12149.
PubMed
Kayserova J, Vcelakova J, Stechova K, Dudkova E, Hromadkova H, Sumnik Z, Kolouskova S, Spisek R, Sediva A: Decreased dendritic cell numbers but increased TLR9-mediated interferon-alpha production in first degree relatives of type 1 diabetes patients. Clin Immunol. 2014 Jul;153(1):49-55.
PubMed
Elias F, Flo J, Lopez RA, Zorzopulos J, Montaner A, Rodriguez JM: Strong cytosine-guanosine-independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs. J Immunol. 2003 Oct 1;171(7):3697-704.
PubMed
Allen JS, Pang K, Skowera A, Ellis R, Rackham C, Lozanoska-Ochser B, Tree T, Leslie RD, Tremble JM, Dayan CM, Peakman M: Plasmacytoid dendritic cells are proportionally expanded at diagnosis of type 1 diabetes and enhance islet autoantigen presentation to T-cells through immune complex capture. Diabetes. 2009 Jan;58(1):138-45.
PubMed
Variant
0.1 mg
1B-305-C100
Out of stock
180.00 USD
0.025 mg
1B-305-C025
Out of stock
90.00 USD
Variant
0.1 mg
11-261-C100
In stock
180.00 USD
0.1 mg
11-261-C100
In stock
90.00 USD
Contact distributor
Datasheet download
SDS download
Bulk requests
Technical support for this product